Compare PCLA & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCLA | ONCY |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.7M | 80.5M |
| IPO Year | 2024 | 2002 |
| Metric | PCLA | ONCY |
|---|---|---|
| Price | $6.05 | $0.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.40 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 02-12-2027 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.37 |
| 52 Week High | $19.61 | $1.30 |
| Indicator | PCLA | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 46.81 | 33.42 |
| Support Level | $6.10 | N/A |
| Resistance Level | $7.19 | $0.89 |
| Average True Range (ATR) | 0.91 | 0.04 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 6.08 | 23.92 |
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.